南财观察｜创新药赛道基金霸榜收益率榜单，风格各不同

Core Insights - The innovative drug funds have emerged as the leading performers in the fund industry this year, with a significant number of fund managers heavily investing in this sector [3][4][5] - As of June 13, 2023, 63 funds have achieved over 50% returns, with 56 of them focusing on innovative drugs, representing nearly 89% of the top performers [3] - Notable fund managers such as Zhang Wei, Liang Furui, and others have shown exceptional performance by investing in innovative drugs, with some funds achieving returns exceeding 99% [5][6] Fund Performance - The top-performing funds include: - Huatai-PB Hong Kong Advantage Selection A (Zhang Wei) with a return of 99.50% - Great Wall Pharmaceutical Industry Selection A (Liang Furui) with 87.73% - Yongying Pharmaceutical Innovation Smart Selection A (Shu Kefa, Dan Lin) with 79.79% [3][5] - The performance of funds focusing on Hong Kong innovative drugs has been particularly strong, with significant interest in the STAR Market's innovative drugs as well [3][4] Fund Manager Strategies - Some fund managers, like Zhang Wei, have adopted a value investment approach and began investing in innovative drugs early, leading to substantial returns [5][6] - Zhang Wei's fund has a high concentration of holdings in innovative drug stocks, with a notable shift in focus beginning in Q1 2023 [6][7] - Other managers, such as Jin Xiaofei, recognized the potential of innovative drugs as early as Q4 2022 and have since adjusted their portfolios accordingly [8][9] Emerging Fund Managers - New generation fund managers like Liang Furui and Zheng Ning have quickly risen to prominence, with Liang's fund achieving a return of 87.73% and Zheng's fund reaching 79.30% [14][15] - Liang Furui's strategy focuses on disruptive innovation and companies with strong commercial potential, while Zheng Ning maintains a diversified portfolio across various pharmaceutical sectors [14][15][16] - The performance of these emerging managers highlights a shift in the fund management landscape, with younger managers capitalizing on new opportunities in the innovative drug sector [13][14]